In a randomised, double-blind, placebo-controlled study (n=455), saxagliptin added to insulin therapy (with or without metformin) in patients with inadequate glycaemic control significantly reduced HbA1c and postprandial glucose levels compared with placebo at week 24. In an extension of the initial study, saxagliptin maintained the reduction in HbA1c levels at week 52 compared with placebo.
Click to search or browse MIMS
The most up-to-date drug information at your fingertips.
- Get the prescribing support you need.
- Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.